Rheumatoid Arthritis

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

Nathan den Broeder, MSs, shares the findings of his study at the ACR 2021 Convergence.

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

Vibeke Strand, MD, explores her ACR presentation, “Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib.”

Joshua Solomon, MD, discusses his upcoming ACR presentation entitled, “A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.”

Data show participants with early glucocorticoid use were more likely to be prescribed a biologic by 12 months, in comparison to non-users.

Theresa Human, PharmD, discusses RediTrex, a subcutaneous injection method of administering methotrexate.

Osteoporosis is a common comorbidity for patients with rheumatoid arthritis. How much do you know about how drugs impact bone health in rheumatoid arthritis?

Patients with rheumatoid arthritis have a higher risk of depression, but how much greater? Take this quiz to test your knowledge of the prevalence of depression.

More patients with methotrexate intolerance receiving baricitinib 4 mg and adalimumab had no progression in radiographic progression at year 5 when compared with placebo.

Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.

Looking specifically at patients who have been treated with biologic disease-modifying anti-rheumatic drugs, this study examines the risk of new or recurrent cancer.

Catch up on Rheumatology Network's most recent highlights in rheumatoid arthritis news.

“In patients with rheumatoid arthritis, the prevalence of depression ranges between 14.8 and 22.5%, which is 2 to 3 times higher than in the general population,” investigators stated.

While the antioxidants in tea may reduce the risk of developing inflammatory diseases, such as rheumatoid arthritis, previous studies have shown inconclusive results.

While lifestyle habits are modifiable risk factors, changing them can be especially challenging for patients with rheumatoid arthritis, who must also deal with chronic inflammatory disease.

Effective treatment for patients with moderate-to-severe rheumatoid arthritis can control symptoms quickly and slow disease progression. How should such patients be managed? Test your knowledge with this quiz.

“The COVID-19 pandemic has strongly impacted the lives of patients living with rheumatoid arthritis which has contributed to anxiety, depression, and reduced well-being.”

Most patients share a fear of falling or psychological distress that can exacerbate physical limitations. In fact, more than half of RA patients report significant fear of falling.

The survey found that 22.3% (n = 62) patients reduced or interrupted treatment and only 3.9% (n = 11) patients stopped treatment entirely. The duration of disease (p = 0.023) and disease activity (p = 0.001) were significant contributing factors in the decision to discontinue treatment.

The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.

Booster doses of the COVID-19 vaccine are recommended for many patients with rheumatoid arthritis. Test your knowledge on who is eligible for a booster and how it should be administered with this quiz.

How much do you know about the treatment of patients with rheumatoid arthritis? Find out now with our quiz.

Test your knowledge with our Rheumatoid Arthritis: 2021 Highlights quiz!

Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.